Natera, Inc. (NASDAQ: NTRA) co-founder Sheena Jonathan has reported a series of stock sales totaling $699,692. The transactions took place on April 27 and April 29, 2026, with the share prices involved ranging from a low of $196.2151 to a high of $204.39. At the time of writing, Natera shares are trading at $194.75, supporting a market capitalization of $27.61 billion. According to Fair Value assessments provided by InvestingPro analysis, Natera is currently listed on the Most Overvalued list.
Transaction Details and Execution
The selling activity was split across two distinct dates in April. On April 27, Ms. Jonathan sold 285 shares at a price of $203.75 per share. On that same day, she disposed of an additional 188 shares at a price of $204.39 per share. These specific sales were primarily intended to cover tax withholding and remittance requirements related to the vesting of Restricted Stock Units (RSUs). The RSUs in question were granted on January 26, 2024, and January 27, 2023. These transactions were carried out under written instructions designed to satisfy the conditions for the Rule 10b5-1(c) affirmative defense.
The second wave of sales occurred on April 29. During this session, Ms. Jonathan sold 2,266 shares at a weighted average price of $196.2151 per share, with individual transaction prices falling between $195.6500 and $196.6250. Additionally, on April 29, she sold 805 shares at a weighted average price of $196.9876 per share, with the individual prices ranging from $196.86 to $197.51. These specific transactions were executed under a Rule 10b5-1 trading plan that had been adopted on December 11, 2024.
Following these completed sales, Ms. Jonathan maintains a direct holding of 255,711 shares of Natera common stock. Furthermore, the Caraluna 1 Trust holds 20,282 shares indirectly, and the Caraluna 2 Trust also holds 20,282 shares; however, Ms. Jonathan disclaims beneficial ownership of these indirect holdings.
Financial Performance and Market Position
The insider activity occurs within a broader context of Natera's recent financial and legal milestones. The company has reported significant revenue growth of 35.9% over the trailing twelve-month period. Despite this top-line expansion, Natera continues to operate without profitability, reporting earnings per share of -$1.52. In terms of market sentiment, William Blair recently initiated coverage on the stock with an Outperform rating, positioning Natera as a core holding for investors focused on growth and noting its robust standing within the diagnostics market.
On the legal front, the United States District Court in the District of Delaware issued a favorable ruling for Natera. The decision grants the company a 30% ongoing royalty from specific sales of certain minimal residual disease-related products by both Invitae and ArcherDx. This ruling follows a prior injunction and applies to certain exceptions.
Governance and Clinical Developments
Natera has also seen changes in its corporate governance structure. The company expanded its board of directors to eleven members following the appointment of Eric Rubin. Serving as a Class I director, Mr. Rubin's term is set to expire in 2028. From a clinical perspective, the company published results in Nature Communications regarding its Signatera circulating tumor DNA assay. These studies focused on the efficacy of the assay in cases of locally advanced rectal cancer and anal squamous cell carcinoma, indicating that patients who tested negative for the assay experienced significant survival benefits.
Key Points
- Insider Dispositions: Co-founder Sheena Jonathan liquidated nearly $700,000 in stock through both tax-related RSU vesting requirements and a pre-arranged 10b5-1 trading plan.
- Growth vs. Profitability: While Natera is seeing strong revenue momentum (35.9% growth), it remains in a loss-making position with negative earnings per share.
- Clinical and Legal Tailwinds: The company has secured favorable royalty rights via court ruling and has published positive clinical data regarding its Signatera assay.
Sector Impact: These developments primarily impact the healthcare diagnostics and biotechnology sectors, influencing how investors value growth-stage medical technology firms.
Risks and Uncertainties
- Valuation Concerns: InvestingPro analysis suggests the stock may be overvalued based on its Fair Value assessment, posing a risk to market participants.
- Profitability Constraints: The company's continued lack of profitability (EPS of -$1.52) represents an ongoing financial uncertainty despite high revenue growth.
Sector Impact: These risks are particularly relevant to the specialty finance and healthcare sectors, where valuation metrics and earnings consistency are critical for capital allocation.